SEC regulator: Gensler's mobile data deleted, including records related to crypto enforcement actions and transparency
Jinse Finance reported that the Office of Inspector General (OIG) of the U.S. Securities and Exchange Commission (SEC) revealed in a report released on Wednesday that the SEC's IT department "implemented an incomprehensible automation policy, resulting in the erasure of data from mobile devices issued by the Gensler administration," deleting stored text messages and operating system logs. The OIG found that some of the deleted texts by Gensler involved SEC enforcement actions against cryptocurrency companies and their founders, meaning that key communications regarding how and when the SEC pursued cases may never be fully known, not even to the courts, Congress, or the public.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Euro: Downside risks with 1.1100 in sight against US Dollar – ING
Swiss Franc weakens as US Dollar (USD) gains on escalating geopolitical conflicts
Swiss Franc: Range-bound within 0.8245–0.8365 band against US Dollar – UOB
BUZZ-Genmab shares hit a three-year high as blood cancer drug combination study results are released
October 6 - Genmab (GMAB.CO) shares rose about 8%, reaching a three-year high and leading the STOXX 600 index (.STOXX). Genmab and AbbVie ABBV.N announced on Monday (link) that their combination therapy for blood cancer reduced the risk of disease progression and death in a late-stage clinical trial. The two companies stated that, compared to R-CHOP regimen alone, the combination therapy reduced the risk of disease progression or death in newly diagnosed patients by 51%. Analysts at Jefferies described this result as "impressive". The brokerage added that the data "easily met the bar for success" and exceeded investor expectations of approximately 40%. TD Cowen stated that the data establishes the combination therapy as a potential new standard of care, with peak market potential expected to exceed $3 billion. (For convenience of non-English speakers, Reuters has automated this report into several other languages. Automated translations may contain errors or lack necessary context, and Reuters makes no guarantees as to their accuracy. The automated translation is provided for reader convenience, and Reuters bears no responsibility for any damages or losses resulting from use of the automated translation.)
Crypto prices
More
